Lluís Ribas is consulted in an article published in Materia about the discovery of a new antibiotic produced by a harmless bacterium present in the human body. This antibiotic acts as a natural defense against other bacteria and opens the door to finding new antibiotics through the analysis of small molecules with bacterial origin in the human body. According to Ribas, an expert on the development of new antibiotics and founder of Omnia Molecular, the potential of this discovery as a way to generate new antibiotics is "incredible."
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).